doi:10.3969/j.issn.1004-583X.2016.01.028

Abstract

CLC Number:

R543.5

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2016.01.028

https://huicui.hebmu.edu.cn/EN/Y2016/V31/I1/108

[1] Poirier S,Mayer G,Benjannet S,et al.The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor(LDLR) and its closest family members VLDLR and ApoER2[J].J Biol Chem,2008,283(4):2363-2372.
[2] Grefhorst A,Mcnutt MC,Lagace TA,et al.Plasma PCSK9 preferentially reduces liver LDL receptors in mice[J].J Lipid Res,2008,49(6):1303-1311.
[3] Benjannet S,Hamelin J,Chretien M,et al.Loss-and gain-of-function PCSK9 variants:cleavage specificity,dominant negative effects,and low density lipoprotein receptor(LDLR) degradation[J].J Bio Chem,2012,287(40):33745-33755.
[4] 李文龙,裴卫东.人类枯草溶菌素转化酶9基因影响胆固醇代谢的研究进展[J].基础医学与临床,2008,28(6):629-632.
[5] Seidah NG,Benjannet S,Wickham L,et al.The secretory proprotein convertase neural apoptosis-regulated convertase 1(NARC-1):liver regeneration and neuronal differentiation[J].Proc Natl Acad Sci USA,2003,100(3):928-933.
[6] Abifadel M,Guerin M,Benjannet S,et al.Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia[J].Atherosclerosis,2012,223(2):394-400.
[7] Kosenko T,Golder M,Leblond G,et al.Low density lipoprotein binds to proprotein convertase subtilisin/kexin type-9(PCSK9)in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation[J].J Biol Chem,2013,288(12):8279-8288.
[8] Leren TP.Sorting an LDL receptor with bound PCSK9 to intracellular degradation[J].Atherosclerosis,2014,237(1):76-81.
[9] Cariou B, Le May C, Costet P.Clinical aspects of PCSK9[J].Atherosclerosis,2011,216(2):258-265.
[10] Zhang Y, Liu J, Li S, et al. Impact of currently prescribed lipid-lowering drugs on plasma PCSK9 concentration:single or in combination study in rats[J]. Lipids Health Dis,2014,13:35-46.
[11] Xu RX, Li S, Zhang Y, et al. Relation of plasma PCSK9 levels to lipoprotein subfractions in patients with stable coronary artery disease[J]. Lipids Health Dis,2014,13:188-204.
[12] Getz GS.PCSK9 in South African variants of familial hypercholesterolemia[J]. J Am Coll Cardiol, 2014,63(22):2374-2375.
[13] Piao MX, Bai JW, Zhang PF,et al. PCSK9 regulates apoptosis in human neuroglioma u251 cells via mitochondrial signaling pathways[J]. Int J Clin Exp Pathol,2015,8(3):2787-2794.
[14] Leren TP.Sorting an LDL receptor with bound PCSK9 to intracellular degradation[J].Atherosclerosis,2014,237(1):76-81.
[15] Araki S, Suga S, Miyake F, et al. Circulating PCSK9 levels correlate with the serum LDL cholesterol level in newborn infants[J]. Early Hum Dev,2014,90(10):607-611.
[16] Kwakernaak AJ,Lambert G,Dullaart RP.Plasma proprotein convertase subtilisin-kexin type 9 is predominantly related to intermediate density lipoproteins[J].Clin Biochem,2014,47(7-8):679-682.
[17] Werner C,Hoffmann MM, Winkler K,et al. Risk prediction with proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with stable coronary disease on statin treatment[J].Vasc Pharmacol,2014,62(2):94-102.
[18] Seidah NG,Benjannet S,Wickham L,et al.The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1) : liver regeneration and neuronal differentiation[J].Proc Natl Acad Sci U S A,2003,100 (3) : 928-933.
[19] Wu Q,Tang ZH,Peng J,et al.The dual behavior of PCSK9 in the regulation of apoptosis is crucial in Alzheimer＇s disease progression (Review)[J].Biomed Rep,2014,2(2):167-171.
[20] Mbikay M,Sirois F,Mayne J,et al.PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities[J].FEBS Lett,2010, 584(4):701-706.
[21] Lagace TA. PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells[J]. Curr Opin Lipidol,2014,25(5):387-393.
[22] 李风梅,刘忠民.人前蛋白转化酶枯草溶菌素9基因的研究进展[J].临床检验杂志, 2014,32(3):219-221.
[23] 江璐,龚慧琴,刘录山.前蛋白转化酶枯草溶菌素9 的生物学功能[J].中国生物化学与分子生物学报,2010,26(12):1085-1089.
[24] Saavedra YG, Zhang J, Seidah NG.PCSK9 prosegment chimera as novel inhibitiors of LDLR degradation[J].PLoS One,2013,8(8):e72113.
[25] Joy TR.Novel therapeutic agents for lowering low density lipoprotein cholesterol[J].Pharmacol Ther,2012,135(1):31-43.
[26] Fatton E,Cappelletti M,Lo Surdo P,et al.Immunization against proprotein convertase subtilisin-like/kexin type 9 lowers plasma LDL-cholesterol levels in mice[J].J Lipid Res,2012,53(8):1654-1661.
[27] Shen L,Peng HC,Nees SN,et al.Proproein convertase subtilisin/kexin type 9 potentially influences cholesterol uptake in macrophages and reverse cholesterol transport[J].FEBS Lett,2013,587(9):1271-1274.
[28] Feingold KR,Moser AH,Shigenaga JK,et al.Inflammation stimulates the expression of PCSK9[J].Biochem Biophys Res Commun,2008,374(2):341-344.
[29] Lan H,Pang L,Smith MM,et al.Proprotein convertase subtilisin/kexin type 9(PCSK9) affects gene expression pathways beyond cholesterol metabolism in liver cells[J].J Cell Physiol,2010,224(1):273-281.
[30] Ranheim T,Mattingsdal M,Lindvall JM,et al.Genome-wide expression analysis of cells expressing gain of function mutant D374Y-PCSK9[J].J Cell Physiol,2008,217(2):459-467.
[31] Tang Z,Jiang L,Peng J,et al.PCSK9 siRNA suppresses the inflammatory response induced by oxLDL through inhibition of NF-κB activation in THP-1-derived macrophages[J].Int J Mol Med,2012,30(4):931-938.
[32] Hampton EN,Knuth MW,Li J,et al.The self-inhibited structure of full-length PCSK9 at 1.9 A reveals structural homology with resistin within the C-terminal domain[J].Proc Natl Acad Sci U S A,2007,104(37):14604-14609.
[33] Lehrke M,Reilly MP,Millington SC,et al.An inflammatory cascade leading to hyperresistinemia in humans[J].PLoS Med,2004,1(2):e45.
[34] Axelsson J,Bergsten A,Qureshi AR,et al.Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate and inflammation,but not with insulin resisance[J].Kidney Int,2006,69(3):596-604.
[35] Tarkowski A,Bjersing J,Shestakov A,et al.Resistin competes with lipopolysaccharide for binding to toll-like receptor 4[J].J Cell Mol Med,2010,14(6B):1419-1431.
[36] 江璐.PCSK9 siRNA抑制ox-LDL诱导的THP-1源性巨噬细胞炎症因子表达与分泌[D].衡阳:南华大学,2011.
[37] Hooper AJ, Burnett JR. Anti-PCSK9 therapies for the treatment of hypercholesterolemia[J]. Expert Opin Biol Ther, 2013, 13( 3) : 429-435.
[38] Cariou B, Le May C, Costet P. Clinical aspects of PCSK9[J]. Atherosclerosis,2011,216(2):258-265.
[39] 范丽娟,李仲. LDL受体介导的血浆低密度脂蛋白胆固醇的内吞[J].生命的化学,2014, 34(3):329-336.
[40] Mullard A. Cholesterol-lowering blockbuster candidates speed into phase Ⅲ trials[J].Nat Rev Drug Discov,2012,11(11):817-819.
[41] Crunkhorn S.Trial watch: PCSK9 antibody reduces LDL cholesterol[J].Nat Rev Drug Discov,2012,11(1):11.
[42] Koren MJ,Lundqvist P,Bolognese M,et al.Anti-PCSK9 monotherap for hypercholesterolemia:the MENDEL-2 randomized,controlled phase Ⅲ clinical trial of evolocumab[J].J Am Coll Cardiol,2014,63(23):2531-2540.
[43] Blom DJ,Hala T,Bolognese M,et al.A 52-week placebocontrolled trail of evolocumab in hyperlipidemia[J].N Engl J Med,2014,370(19):1809-1819.
[44] 刘兴兰,谷文,雷寒,等. Evolocumab降低低密度脂蛋白胆固醇有效性与安全性的Meta分析[J].临床荟萃,2015,30(5):481-485.
[45] Koren MJ,Lundqvist P,Bolognese M,et al. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab[J]. J Am Coll Cardiol, 2014,63(23):2531-2540.
[46] Hirayama A,Honarpour N,Yoshida M,et al.Effects of evolocumab(AMG145),a monoclonal antibody to PCSK9,in hypercholesterolemic,statin-treated Japanese patients at high Cardiovascular risk[J].Circ J,2014,78(5):1073-1082.
[47] Schwartz GG, Bessac L, Berdan LG,et al. Effect of alirocumab,a monoclonal antibody to PCSK9,on long-term cardiovascular outcomes following acute coronary syndromes:Rationale and design of the ODYSSEY Outcomes trial[J].Am Heart J,2014,168(5):682-689.
[48] Fitzgerald K,Frank-Kamenetsky M,Shulga-Morskaya S,et al.Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type9(PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers:a randomised,single-blind,placebo-controlled,phase 1 trial[J].Lancet,2014,383(9911):60-68.

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Li Zhiyong. Transient peripheral carotid inflammation syndrome diagnosed by ultrasonography: A case report and literature review [J]. Clinical Focus, 2023, 38(11): 1027-1030.
[2]	Zhang Lei, Lou Haidong, Zhi Yu, Qi Shuying. Efficacy and safety of PCSK9 inhibitors on atherosclerotic cardiovascular disease: A meta-analysis [J]. Clinical Focus, 2022, 37(12): 1074-1080.
[3]	. [J]. Clinical Focus, 2022, 37(10): 950-952.
[4]	Chen Jun, Zhou Yiwei, Li Xiujuan. Analysis of antithrombotic therapy for symptomatic lower extremity atherosclerosis disease [J]. Clinical Focus, 2021, 36(10): 937-941.
[5]	Xu Yaoming, Du Yanqiu, Miu Zhongrong, Gao Feng. Clinical analysis of endovascular recanalization for chronic intracranial segment of intracranial artery occlusion [J]. Clinical Focus, 2021, 36(1): 30-34.
[6]	. [J]. Clinical Focus, 2016, 31(4): 456-457.
[7]	Zhang Xueqiang;Wang Jianfeng. Application of multiple endovascular techniques in treatment of acute and chronic lower extremity arterial thrombosis [J]. Clinical Focus, 2015, 30(11): 1283-1287.
[8]	. [J]. Clinical Focus, 2015, 30(6): 680-682.
[9]	. [J]. Clinical Focus, 2015, 30(6): 682-683.
[10]	. [J]. Clinical Focus, 2015, 30(3): 339-340.
[11]	. [J]. Clinical Focus, 2015, 30(3): 341-344.
[12]	. @@ [J]. Clinical Focus, 2014, 29(12): 1423-1426.
[13]	. [J]. Clinical Focus, 2014, 29(7): 826-829.
[14]	. [J]. Clinical Focus, 2014, 29(7): 833-837.
[15]	. [J]. Clinical Focus, 2014, 29(5): 599-601.